IP Library Granted Patent US 8,728,819
Granted Patent B2
US 8,728,819 · App. 12/438,932 · Granted May 20, 2014

Methods for culturing minimally-passaged fibroblasts and uses thereof

Inventors: John Maslowski (Pottstown, PA); Myrna F. Thomas (Hainesport, NJ); Marie A. Lindner (Radnor, PA)
Assignee: Fibrocell Technologies, Inc.
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,728,819
App. No.
12/438,932
Granted
May 20, 2014
Kind
B2
Abstract

The present invention relates to novel methods of growing at least 100 million minimally-passaged fibroblasts from a small biopsy specimen. The invention includes methods wherein a small biopsy specimen is seeded directly into a large tissue culture flask, and passaged no more than three times.

Claims (15)

1. A cell-free topical composition comprising derived from at most passage three fibroblasts conditioned medium produced by a method comprising the steps of:

a) digesting a tissue biopsy specimen with a dissociative or digestive enzyme to form a fibroblast cell suspension, wherein the biopsy specimen is a single full-thickness biopsy not more than 5 mm thick and not more than 12 cm 2 ;

b) seeding the fibroblast cell suspension into a first tissue culture flask containing a medium;

c) culturing a fibroblast cell population in the first tissue culture flask through at most three passages into sequentially larger tissue culture flasks in the medium, thereby generating at least 100 million minimally-passaged fibroblasts and a conditioned medium;

d) harvesting said at least 100 million minimally-passaged fibroblasts to obtain a cell-free conditioned medium; and

e) formulating the conditioned medium for topical administration to obtain the cell-free topical composition.

2. The composition of claim 1 , wherein the enzyme is a collagenase.

3. The composition of claim 2 , wherein the collagenase is liberase.

4. The composition of claim 1 , wherein the enzyme is trypsin.

5. The composition of claim 1 , wherein at least 200 million minimally-passaged fibroblasts are generated.

6. The composition of claim 1 , wherein at least one billion minimally-passaged fibroblasts are generated.

7. The composition of claim 1 , wherein the first tissue culture flask is a T-175 or a T-225 flask.

8. The composition of claim 7 , wherein the sequentially larger tissue culture flasks are a T-500 flask or a 10-layer cell culture stack.

9. The composition of claim 1 , wherein the first tissue culture flask is a T-175 or a T-225 flask, the sequentially larger tissue culture flasks are a T-500 flask or multilayer cell culture stacks cell culture stack, and wherein the multilayer stacks are 10-layer stacks.

10. The composition of claim 1 , wherein the at least 100 million minimally-passaged fibroblasts are generated by culturing the fibroblast cell population in the first tissue culture flask through no more than three passages into sequentially larger tissue culture flasks.

Assignments (8)
SECURITY INTEREST Recorded Mar 31, 2025
From: CASTLE CREEK BIOSCIENCES, LLC
To: LIGAND PHARMACEUTICALS INCORPORATED
Reel/Frame 070680/0695 →
SECURITY INTEREST Recorded Feb 25, 2025
From: CASTLE CREEK BIOSCIENCES, INC.
To: HORIZON TECHNOLOGY FINANCE CORPORATION
Reel/Frame 070317/0737 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 18, 2021
From: FIBROCELL TECHNOLOGIES, INC.
To: FIBROCELL SCIENCE, INC.
Reel/Frame 055641/0367 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 18, 2021
From: FIBROCELL SCIENCE, INC.
To: CASTLE CREEK BIOSCIENCES, LLC
Reel/Frame 055642/0372 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 26, 2013
From: FIBROCELL SCIENCE, INC.
To: FIBROCELL TECHNOLOGIES, INC.
Reel/Frame 030082/0988 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 20, 2012
From: MASLOWSKI, JOHN
To: FIBROCELL SCIENCE, INC.
Reel/Frame 028413/0098 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 9, 2012
From: LINDNER, MARIE A.; THOMAS, MYRNA F.
To: ISOLAGEN, INC.
Reel/Frame 028183/0142 →
CHANGE OF NAME Recorded Jul 15, 2011
From: ISOLAGEN, INC.
To: FIBROCELL SCIENCE, INC.
Reel/Frame 026601/0287 →
Continuity (2)
Provisional Application 60823871 · Aug 29, 2006
Related Publication 20100297088A1 · Nov 25, 2010